Explore how TNX-102 SL aims to improve major depressive disorder by enhancing slow-wave sleep, as the HORIZON phase 2 trial tests nightly dosing.
Gregory Sullivan, MD
Advertisement
Articles by Gregory Sullivan, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
Attachment-Based Therapy in Adolescent Substance Users: A Meta-Synthesis of Emotional Isolation and Avoidant Attachment Patterns
2
Positive Safety and Biomarker Phase 1b Results for PMN310 Mild Cognitive Impairment and Alzheimer Disease
3
Novel CSF Biomarker and Peptide Candidate Target Cognitive Symptoms of Schizophrenia
4
Quiet Comfort: New Details on COMP360 Psilocybin Administration Sessions for the Treatment of PTSD
5